Placenta-Derived Protein Offers New Hope for Spinal Cord Repair

For decades, spinal cord injuries have represented one of medicine’s most intractable challenges. Now, a groundbreaking development originating in Brazil offers a potential turning point: a first-in-the-world drug, polylaminin, designed to regenerate damaged spinal cords and restore lost function. This therapy, derived from an unexpected source – the human placenta – has demonstrated remarkable results in early trials, offering new hope to individuals living with paralysis.

Decades of Dedicated Research

Unlocking the Potential of Laminin

The breakthrough is the culmination of 25 years of research led by Dr. Tatiana Coelho de Sampaio, a PhD professor at the Federal University of Rio de Janeiro. Dr. De Sampaio and her team focused on laminin, a protein crucial for the nervous system’s ability to repair and regenerate. Research, as reported by Folha de S.Paulo, revealed laminin’s significant capacity to support neural recovery.

Did You Know? The research team’s work began 25 years ago, focusing on the regenerative properties of laminin.

Polylaminin: A Novel Approach to Spinal Cord Repair

From Placenta to Potential Cure

Building on their understanding of laminin, researchers developed polylaminin, a bioengineered protein derived from human placental tissue. Cristália Laboratory presented the therapy on September 9, 2025, highlighting its potential to address spinal cord injuries resulting from accidents. These injuries frequently lead to paraplegia – paralysis of the lower limbs – or quadriplegia, impacting both upper and lower limbs.

Expert Insight: The use of placental proteins represents a novel approach to neurological repair, potentially offering advantages over traditional therapies like stem cell transplantation by minimizing the risk of rejection.

Remarkable Results in Experimental Trials

During experimental trials, polylaminin was administered directly to the spinal cords of patients. The results were striking: patients experienced complete recovery of motor function, with no lasting aftereffects. Individuals were able to resume their daily routines without physical limitations, suggesting a potentially transformative impact on the lives of those with spinal cord injuries.

What Might Come Next?

While the initial results are promising, further clinical trials are necessary to confirm the safety and efficacy of polylaminin. Anvisa, the Brazilian health regulatory agency, still needs to authorize these trials. If successful, polylaminin could become the first approved drug for spinal cord regeneration, potentially revolutionizing treatment for individuals with paraplegia and quadriplegia. Wider availability of the drug will likely depend on the scale-up of production and distribution capabilities.

Frequently Asked Questions

What is polylaminin?

Polylaminin is a bioengineered protein derived from human placental tissue, designed to interact with neural cells in the spinal cord.

What types of injuries did the trials focus on?

The experimental trials involved patients with paraplegia and quadriplegia caused by spinal cord ruptures.

How was the treatment administered?

Polylaminin was administered directly to the spinal cord during the experimental phase.

Could this breakthrough fundamentally change how we approach and treat debilitating spinal cord injuries?